Joana Maia1,2, Andreia Hanada Otake1,3, Juliana Poças4,5,6, Ana Sofia Carvalho7, Hans Christian Beck8, Ana Magalhães4,5, Rune Matthiesen7, Maria Carolina Strano Moraes1 and Bruno Costa-Silva1
1-Champalimaud Centre for the Unknown, Champalimaud Foundation, Lisbon, Portugal
2-Graduate Program in Areas of Basic and Applied Biology, University of Porto, Porto, Portugal
O cancro de pâncreas é a quarta principal causa de mortes relacionadas ao cancro no mundo, apresentando uma taxa de sobrevida de 5 anos de cerca de 6% e uma taxa de sobrevida média de cerca de 6 meses. Entre os cancros pancreáticos, o adenocarcinoma ductal pancreático (CP) é o tipo mais comum e é responsável por mais de 90% dos casos. Uma combinação de fatores leva ao mau prognóstico do CP, incluindo dificuldades na deteção da doença em estágio inicial, seu alto potencial metastático e sua resistência às terapias convencionais.
Major alterations in cell glycosylation occurring during cancer development and progression represent key features of tumor cell malignant behavior. In this publication, the authors preview and put in context the findings of Agrawal et al. (Cancer Cell, Vol. 31, Issue 6, 2017) that identified and characterized a novel molecular mechanism in which aberrant glycosylation actively tunes the metastatic capacity of melanoma cells by preventing the proteolytic cleavage of the L1CAM adhesion molecule.
Major alterations in cell glycosylation occurring during cancer development and progression represent key features of tumor cell malignant behavior. In this publication, the authors preview and put in context the findings of Agrawal et al. (Cancer Cell, Vol. 31, Issue 6, 2017) that identified and characterized a novel molecular mechanism in which aberrant glycosylation actively tunes the metastatic capacity of melanoma cells by preventing the proteolytic cleavage of the L1CAM adhesion molecule.
Filipe Pinto1,2 Nathalia C. Campanella3 Lucas F. Abrahão-Machado4 Cristovam Scapulatempo-Neto3,4 Antonio T. de Oliveira3,5 Maria J. Brito6 Raquel P. Andrade7 Denise P. Guimarães3,8 Rui M. Reis1,2,3
1 Life and Health Sciences Research Institute (ICVS), School of Health Sciences, University of Minho, Braga, Portugal
2 ICVS/3B’s-PT Government Associate Laboratory, Braga, Guimara˜es, Portugal
O factor de transcrição Brachyury foi recentemente descrito como estando sobre-expresso e associado com pior prógnostico em tumores sólidos. No presente estudo avaliamos o potencial valor de prognóstico de Brachyury em tumores do estroma gastrointestinal (GIST).
